Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib
- 11 January 2005
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 74 (2) , 121-123
- https://doi.org/10.1111/j.1600-0609.2004.00351.x
Abstract
Abstract: Imatinib related non‐haematological side‐effects are reported in <10% of chronic myeloid leukaemia patients and include oedema, weight gain, nausea, vomiting and muscle cramps. Cutaneous reactions are well‐recognized events occurring mostly in patients treated at doses of 600 mg/d and higher, either in stable or progressive disease. We report on our experience relating to dermatological toxicities in imatinib treated CML patients showing a spectrum of skin reactions ranging from rashes to cutaneous carcinoma.Keywords
This publication has 10 references indexed in Scilit:
- Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phaseCancer, 2003
- Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantationAnnals of Hematology, 2003
- Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatmentEuropean Journal of Haematology, 2003
- A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (sti 571, glivec®)British Journal of Haematology, 2003
- Stevens–Johnson syndrome after treatment with STI571: a case reportBritish Journal of Haematology, 2002
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Hyaline Cell-rich Chondroid Syringoma: Case Report and Review of the LiteraturePathology - Research and Practice, 2002
- Cutaneous Reactions to STI571New England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001